Developer docs
API playgroundTry for free, no card

Search company profiles

Proof Diagnostics

Full company profile

uuid00025e4

Namestring
Proof Diagnostics
Legal namestring
Proof Diagnostics, Inc.
Websiteurl
proofdx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Proof Diagnostics was a Cambridge, Massachusetts-based health technology company founded in 2019 by leading CRISPR and gene editing researchers, including Dr. Feng Zhang of the Broad Institute of MIT and Harvard, Drs. Omar Abudayyeh and Jonathan Gootenberg of the McGovern Institute for Brain Research at MIT, and CEO Sid Shenai. The company developed a portable, CRISPR-based molecular diagnostic platform — the Proof Lab Test System — designed to deliver results within 18 minutes for SARS-CoV-2, Flu A/B, RSV, and oncology applications at the point of care. Its underlying scientific asset was the OMEGA (Obligate Mobile Element Guided Activity) RNA-programmable nuclease platform, a class of non-Cas enzymes that are smaller, more diverse, and more robust than conventional CRISPR Cas nucleases, making them more amenable to delivery into cells for gene editing applications.

The company's commercial model combined hardware sales of portable diagnostic devices for healthcare providers and point-of-care facilities with a longer-term licensing and tool-development pathway for its OMEGA enzyme libraries. The company submitted an FDA Emergency Use Authorization application for its COVID-19 diagnostic in April 2022 and raised a $45 million Series A from ARCH Venture Partners, F-Prime, and Madrona. Following Ginkgo Bioworks' (NYSE: DNA) acquisition in February 2024, Proof's OMEGA nuclease libraries have been integrated into Ginkgo's Gene Therapy Services platform to serve pharmaceutical and biotechnology customers developing genetic medicines, while the portable diagnostic system has been incorporated into Ginkgo's biosecurity and cell programming platform. As of April 2025, Proof Diagnostics continues to operate as a semi-autonomous subsidiary within Ginkgo Bioworks, retaining its own executive team.

Short descriptiontext

Proof Diagnostics, founded in 2019 and acquired by Ginkgo Bioworks in February 2024, developed CRISPR-based molecular diagnostic platforms and proprietary OMEGA RNA-programmable nuclease technology for point-of-care infectious disease testing and gene therapy applications.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
CRISPR diagnostics, molecular diagnostics, point-of-care testing, gene editing tools, infectious disease detection
Industry2 codes
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Molecular Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Molecular Diagnostic Testing Products
TypeHardware Sales
Description

Proof Diagnostics developed and commercialized molecular diagnostic tests using CRISPR technology for infectious disease detection. The company submitted an EUA application to the FDA for its Proof Lab Test System, targeting point-of-care testing markets.

investors.ginkgobioworks.com
2Technology Licensing (via Acquisition)
TypeLicensing Royalties
Description

Following acquisition by Ginkgo Bioworks in February 2024, Proof's OMEGA nuclease technology is being integrated into Ginkgo's Gene Therapy Services platform, providing customers with new gene editing tools for therapeutic applications.

investors.ginkgobioworks.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Proof Diagnostics develops a portable, CRISPR-based molecular diagnostic test system (the Proof Lab Test System) that delivers infectious disease detection results within 18 minutes at the point of care. The company's foundational IP is its proprietary OMEGA (Obligate Mobile Element Guided Activity) RNA-programmable, non-Cas nuclease libraries, which are significantly smaller and more diverse than conventional CRISPR Cas nucleases and are now deployed via Ginkgo Bioworks' Gene Therapy Services for therapeutic gene editing applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Results delivered within 18 minutes for COVID-19 molecular diagnostic testing
Product overview1 text field

Proof Diagnostics offers a CRISPR-based molecular diagnostic platform designed for portable, rapid point-of-care testing. The core product is the Proof Lab Test System, a molecular diagnostic device that delivers results in 18 minutes for infectious diseases including SARS-CoV-2, Flu A/B, and RSV. Underlying this diagnostic work is the company's OMEGA (Obligate Mobile Element Guided Activity) RNA-programmable nuclease technology—a smaller, more diverse class of programmable nucleases compared to CRISPR Cas systems. In February 2024, Proof Diagnostics was acquired by Ginkgo Bioworks, which is integrating the OMEGA nuclease technology into its gene therapy services to provide customers with expanded gene editing tools.

Product and service1 record
1Proof Lab Test System
CategoryPoint-of-Care Diagnostic Device
Description

A portable, CRISPR-based molecular diagnostic test system designed to provide fast, accurate results within 18 minutes for infectious diseases including SARS-CoV-2, with intended expansion to Flu A/B, RSV, and oncology applications. Built for simple, scalable point-of-care testing in healthcare facilities, clinics, and decentralized settings.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CRISPR-based molecular diagnostics company developing SHERLOCK and INSPECTR platforms for infectious disease and oncology detection. Directly comparable to Proof's CRISPR diagnostic platform and similar Cambridge-based, founder-led positioning.

TypeDirect peer
Description

CRISPR-based diagnostics and gene-editing therapeutics company co-founded by Jennifer Doudna. Directly comparable on CRISPR diagnostics technology and CRISPR-based platform play.

TypeDirect peer
Description

CRISPR-based diagnostics company developing portable molecular tests for infectious diseases. Comparable to Proof's portable, CRISPR-based point-of-care testing strategy.

4Cue Health
TypeDirect peer
Description

Portable molecular point-of-care diagnostic system for respiratory and other infectious diseases. Directly comparable to Proof Lab Test System on form factor, target disease menu, and POC channel.

TypeDirect peer
Description

Developer of single-use, PCR-based portable molecular diagnostic tests for infectious diseases. Comparable to Proof's portable molecular POC platform on use case and customers.

TypeDirect peer
Description

Discovery and development of novel CRISPR nucleases and gene editors for therapeutic applications. Closely comparable to Proof's OMEGA nuclease platform and is already a Ginkgo partner in precision gene editors.

TypeBroad incumbent
Description

Established molecular diagnostics incumbent with the GeneXpert system widely deployed across hospitals and POC settings. Represents the entrenched competition Proof must displace in clinical molecular diagnostics.

8Abbott Diagnostics
TypeBroad incumbent
Description

Major diagnostics incumbent offering the ID NOW rapid molecular POC platform and broad respiratory testing menu. Represents scale and channel competition against Proof Lab Test System.

TypeEmerging player
Description

Clinical-stage gene editing company co-founded by Dr. Feng Zhang. Comparable on programmable nuclease modality and shared founder pedigree, though focused on therapeutic development rather than diagnostics.

TypeEmerging player
Description

Clinical-stage base editing company developing programmable precision genetic medicines. Comparable as a programmable nuclease platform player pursuing therapeutic applications, similar to OMEGA's gene therapy trajectory.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Proof Diagnostics

Molecular Diagnosticsproofdx.com

Proof Diagnostics, founded in 2019 and acquired by Ginkgo Bioworks in February 2024, developed CRISPR-based molecular diagnostic platforms and proprietary OMEGA RNA-programmable nuclease technology for point-of-care infectious disease testing and gene therapy applications.

What Proof Diagnostics does

Proof Diagnostics was a Cambridge, Massachusetts-based health technology company founded in 2019 by leading CRISPR and gene editing researchers, including Dr. Feng Zhang of the Broad Institute of MIT and Harvard, Drs. Omar Abudayyeh and Jonathan Gootenberg of the McGovern Institute for Brain Research at MIT, and CEO Sid Shenai. The company developed a portable, CRISPR-based molecular diagnostic platform — the Proof Lab Test System — designed to deliver results within 18 minutes for SARS-CoV-2, Flu A/B, RSV, and oncology applications at the point of care. Its underlying scientific asset was the OMEGA (Obligate Mobile Element Guided Activity) RNA-programmable nuclease platform, a class of non-Cas enzymes that are smaller, more diverse, and more robust than conventional CRISPR Cas nucleases, making them more amenable to delivery into cells for gene editing applications.

The company's commercial model combined hardware sales of portable diagnostic devices for healthcare providers and point-of-care facilities with a longer-term licensing and tool-development pathway for its OMEGA enzyme libraries. The company submitted an FDA Emergency Use Authorization application for its COVID-19 diagnostic in April 2022 and raised a $45 million Series A from ARCH Venture Partners, F-Prime, and Madrona. Following Ginkgo Bioworks' (NYSE: DNA) acquisition in February 2024, Proof's OMEGA nuclease libraries have been integrated into Ginkgo's Gene Therapy Services platform to serve pharmaceutical and biotechnology customers developing genetic medicines, while the portable diagnostic system has been incorporated into Ginkgo's biosecurity and cell programming platform. As of April 2025, Proof Diagnostics continues to operate as a semi-autonomous subsidiary within Ginkgo Bioworks, retaining its own executive team.

Proof Diagnostics firmographics

Firmographics
Name
Proof Diagnostics
Legal name
Proof Diagnostics, Inc.
Website
https://proofdx.com
Company type
Private
Founded year
2019
Operating status
Acquired
Headcount range
1–10 employees
Short description
Proof Diagnostics, founded in 2019 and acquired by Ginkgo Bioworks in February 2024, developed CRISPR-based molecular diagnostic platforms and proprietary OMEGA RNA-programmable nuclease technology for point-of-care infectious disease testing and gene therapy applications.
Ownership category
akta.pro rank

Where Proof Diagnostics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Proof Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Molecular Diagnostic Testing Products: Proof Diagnostics developed and commercialized molecular diagnostic tests using CRISPR technology for infectious disease detection. The company submitted an EUA application to the FDA for its Proof Lab Test System, targeting point-of-care testing markets.
  2. Technology Licensing (via Acquisition): Following acquisition by Ginkgo Bioworks in February 2024, Proof's OMEGA nuclease technology is being integrated into Ginkgo's Gene Therapy Services platform, providing customers with new gene editing tools for therapeutic applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Proof Diagnostics product offering

Product offering

Core offering

Proof Diagnostics develops a portable, CRISPR-based molecular diagnostic test system (the Proof Lab Test System) that delivers infectious disease detection results within 18 minutes at the point of care. The company's foundational IP is its proprietary OMEGA (Obligate Mobile Element Guided Activity) RNA-programmable, non-Cas nuclease libraries, which are significantly smaller and more diverse than conventional CRISPR Cas nucleases and are now deployed via Ginkgo Bioworks' Gene Therapy Services for therapeutic gene editing applications.

Product overview

Proof Diagnostics offers a CRISPR-based molecular diagnostic platform designed for portable, rapid point-of-care testing. The core product is the Proof Lab Test System, a molecular diagnostic device that delivers results in 18 minutes for infectious diseases including SARS-CoV-2, Flu A/B, and RSV. Underlying this diagnostic work is the company's OMEGA (Obligate Mobile Element Guided Activity) RNA-programmable nuclease technology—a smaller, more diverse class of programmable nucleases compared to CRISPR Cas systems. In February 2024, Proof Diagnostics was acquired by Ginkgo Bioworks, which is integrating the OMEGA nuclease technology into its gene therapy services to provide customers with expanded gene editing tools.

Differentiator

Problem solved

Functional benefit

Products and services

  • Proof Lab Test System A portable, CRISPR-based molecular diagnostic test system designed to provide fast, accurate results within 18 minutes for infectious diseases including SARS-CoV-2, with intended expansion to Flu A/B, RSV, and oncology applications. Built for simple, scalable point-of-care testing in healthcare facilities, clinics, and decentralized settings.

Quantifiable outcome

  • Results delivered within 18 minutes for COVID-19 molecular diagnostic testing

Companies that use Proof Diagnostics

Customer profile

Segments2 records

Ideal customer profiles2 records

Proof Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Proof Diagnostics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Proof Diagnostics competitors and assessment

Company assessment

Direct peers

  • Sherlock Biosciences: CRISPR-based molecular diagnostics company developing SHERLOCK and INSPECTR platforms for infectious disease and oncology detection. Directly comparable to Proof's CRISPR diagnostic platform and similar Cambridge-based, founder-led positioning.
  • Mammoth Biosciences: CRISPR-based diagnostics and gene-editing therapeutics company co-founded by Jennifer Doudna. Directly comparable on CRISPR diagnostics technology and CRISPR-based platform play.
  • Caspr Biotech: CRISPR-based diagnostics company developing portable molecular tests for infectious diseases. Comparable to Proof's portable, CRISPR-based point-of-care testing strategy.
  • Cue Health: Portable molecular point-of-care diagnostic system for respiratory and other infectious diseases. Directly comparable to Proof Lab Test System on form factor, target disease menu, and POC channel.
  • Visby Medical: Developer of single-use, PCR-based portable molecular diagnostic tests for infectious diseases. Comparable to Proof's portable molecular POC platform on use case and customers.
  • Arbor Biotechnologies: Discovery and development of novel CRISPR nucleases and gene editors for therapeutic applications. Closely comparable to Proof's OMEGA nuclease platform and is already a Ginkgo partner in precision gene editors.

Broad incumbents

  • Cepheid (Danaher): Established molecular diagnostics incumbent with the GeneXpert system widely deployed across hospitals and POC settings. Represents the entrenched competition Proof must displace in clinical molecular diagnostics.
  • Abbott Diagnostics: Major diagnostics incumbent offering the ID NOW rapid molecular POC platform and broad respiratory testing menu. Represents scale and channel competition against Proof Lab Test System.

Emerging players

  • Editas Medicine: Clinical-stage gene editing company co-founded by Dr. Feng Zhang. Comparable on programmable nuclease modality and shared founder pedigree, though focused on therapeutic development rather than diagnostics.
  • Beam Therapeutics: Clinical-stage base editing company developing programmable precision genetic medicines. Comparable as a programmable nuclease platform player pursuing therapeutic applications, similar to OMEGA's gene therapy trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Proof Diagnostics social profiles

Digital presence

Proof Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Proof Diagnostics leadership team

Management profile

Number of profiles

Profiles6 records

Proof Diagnostics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Proof Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Proof Diagnostics

What does Proof Diagnostics do?

Proof Diagnostics develops a portable, CRISPR-based molecular diagnostic test system (the Proof Lab Test System) that delivers infectious disease detection results within 18 minutes at the point of care. The company's foundational IP is its proprietary OMEGA (Obligate Mobile Element Guided Activity) RNA-programmable, non-Cas nuclease libraries, which are significantly smaller and more diverse than conventional CRISPR Cas nucleases and are now deployed via Ginkgo Bioworks' Gene Therapy Services for therapeutic gene editing applications.

Is Proof Diagnostics a public or private company?

Proof Diagnostics is a private company. It is classified as corporate owned and is currently acquired.

When was Proof Diagnostics founded?

Proof Diagnostics was founded in 2019. It employs 1 to 10 people.

Where is Proof Diagnostics based?

Proof Diagnostics is headquartered in Cambridge, United States, in the North America region.

How does Proof Diagnostics make money?

Two revenue lines are on record. Molecular Diagnostic Testing Products are the primary driver. The others are technology Licensing (via Acquisition).

Who are Proof Diagnostics's main competitors?

Direct peers on record are Sherlock Biosciences, Mammoth Biosciences, Caspr Biotech, Cue Health, Visby Medical and Arbor Biotechnologies. Broad incumbents are Cepheid (Danaher) and Abbott Diagnostics. Emerging players are Editas Medicine and Beam Therapeutics.

Does Proof Diagnostics have an API?

No public API is recorded for Proof Diagnostics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comSegmentation, Major Trends, and Competitive Overview of the CRISPR-Based Diagnostics MarketThe CRISPR-based diagnostics market is projected to grow to $11.45 billion by 2030, driven by a compound annual growth rate of 17.5%, with key drivers including decentralized testing models, point-of-care diagnostics, and integration with digital health platforms. In February 2024, Ginkgo Bioworks Holdings Inc. acquired Proof Diagnostics Inc. to strengthen its gene therapy offerings by incorporating Proof Diagnostics' OMEGA RNA-programmable nuclease technology. The market report identifies emerging trends such as isothermal amplification techniques, personalized diagnostic applications, and AI integration in diagnostics.openPR.comTrends in Growth, Segment Analysis, and Competitive Strategies Influencing the Cas Nuclease MarketIn February 2024, US-based biotechnology company Ginkgo Bioworks acquired Proof Diagnostics Inc. for an undisclosed amount to strengthen its gene editing capabilities by incorporating Proof Diagnostics' Omega ribonucleic acid (RNA) programmable nuclease libraries and CRISPR-based platforms. The Cas Nuclease market is projected to reach $9.2 billion by 2030, growing at a compound annual growth rate (CAGR) of 18.8%, driven by increased investments in precision medicine, expanding gene therapy pipelines, and clearer regulatory guidelines for genome editing.CDO MagazineProof Diagnostics Hires Adam Henry as SVP of Corporate DevelopmentProof Diagnostics, Inc., a healthcare technology company specializing in molecular diagnostics, announced the appointment of Adam Henry as Senior Vice President of Corporate Development. Henry brings over 25 years of experience in health tech and diagnostics, having previously held senior roles at Roche subsidiary GenMark Dx, Siemens Healthineers, and Hologic/Gen-Probe. He will lead the company's growth and business development strategy and will report directly to CEO and co-founder Sid Shenai.FinSMEsGinkgo Bioworks Acquires Proof DiagnosticsGinkgo Bioworks has acquired Proof Diagnostics to expand its gene editing service offerings. Proof Diagnostics was founded by researchers from the Broad Institute and MIT to develop CRISPR-based diagnostic systems for various diseases. The financial terms of the acquisition were not disclosed.TmcnetGinkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its CustomersGinkgo Bioworks acquired Proof Diagnostics, a diagnostics and gene editing tools company founded by Feng Zhang and others. The acquisition adds Proof's OMEGA RNA programmable non-Cas enzyme libraries to Ginkgo's gene therapy services, expanding its gene editing toolkit. Ginkgo will integrate these technologies to help customers develop next-generation gene therapies.YahooGinkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its CustomersGinkgo Bioworks acquired Proof Diagnostics, a company developing CRISPR-based diagnostics and OMEGA RNA programmable nucleases. Ginkgo will integrate Proof's OMEGA libraries into its gene therapy services, expanding its gene editing toolkit. The acquisition aims to provide customers with new tools for gene editing and therapeutic development.American City Business JournalsGinkgo Bioworks acquires Proof Diagnostics, Patch Biosciences, key assets of Reverie Labs, and launches new technology networkGinkgo Bioworks acquired Proof Diagnostics, key assets of Reverie Labs, and Patch Biosciences, and launched the Ginkgo Technology Network. The deals expand its gene editing, AI/ML drug discovery, and sequence design offerings, with financial terms undisclosed.YahooGinkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its CustomersGinkgo Bioworks acquired Proof Diagnostics, a diagnostics and gene editing tools company founded by Feng Zhang and others. The acquisition adds Proof's OMEGA RNA programmable non-Cas enzyme libraries to Ginkgo's gene therapy services, expanding its gene editing toolkit. Ginkgo will integrate these technologies to help customers develop next-generation therapies.PR NewswireGinkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its CustomersGinkgo Bioworks acquired Proof Diagnostics, a diagnostics and gene editing tools company founded by Feng Zhang and others. Ginkgo will integrate Proof's OMEGA RNA programmable non-Cas enzyme libraries into its gene therapy services, expanding its gene editing toolkit. The acquisition aims to provide customers with more compact and diverse tools for gene editing.PR NewswirePROOF DIAGNOSTICS EXPANDS LEADERSHIP TEAM WITH STRATEGIC GROWTH HIREProof Diagnostics, a healthcare technology company based in Cambridge, Massachusetts, has appointed Adam Henry as Senior Vice President of Corporate Development to lead its growth and business development strategy. Henry brings over 25 years of experience in the diagnostics and health tech sector, having previously held senior roles at Roche-subsidiary GenMark Dx, Siemens Healthineers, and Hologic. He will report directly to CEO and co-founder Sid Shenai as the company seeks to accelerate its corporate development initiatives and expand its molecular diagnostics business.